Memory Pharmaceuticals 8-K 2008
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Memory Pharmaceuticals Corp.
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Item 8.01 Other Events.
On December 24, 2008, Memory Pharmaceuticals Corp. (the "Registrant"), issued a press release announcing that the Registrant has dosed the first patient in its Phase 2 clinical study of the effect of R3487/MEM 3454, a nicotinic alpha-7 partial agonist, on electrophysiological biomarkers in patients with schizophrenia. The study will evaluate the effect of four doses of R3487/MEM 3454 on electrophysiological biomarkers (such as P50 sensory gating) that have been shown to be closely associated with schizophrenia. A copy of the press release that includes this announcement is attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits.
99.1 Press release dated December 24, 2008.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.